SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIAL

被引：0
|
作者：
Yamada, Y.
Yoshino, T. [1 ]
Komatsu, Y. [2 ]
Yamazaki, K. [3 ]
Tsuji, A. [4 ]
Ura, T. [5 ]
Grothey, A. [6 ]
Van Cutsem, E. [7 ]
Wagner, A. [8 ]
Ohtsu, A. [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[3] Shizuoka Canc Ctr, Shizuoka, Japan
[4] Kochi Hlth Sci Ctr, Kochi, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Mayo Clin Rochester, Rochester, MN USA
[7] Univ Hosp Gasthuisberg, Gasthuisberg, Belgium
[8] Bayer Pharma AG, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
10.1093/annonc/mdt459.81
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Single nucleotide polymorphism (SNP) analysis identifies potential prognostic and predictive biomarker in patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib in the phase III CORRECT trial
    Battaglin, F.
    Zhang, W.
    Skubala, A.
    Arai, H.
    Wang, J.
    Soni, S.
    Wang, Y. A.
    Koechert, K.
    Schulz, A.
    Teufel, M.
    Millstein, J.
    Lenz, H. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S439 - S439
  • [32] Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
    Skarderud, Maria Roed
    Polk, Anne
    Vistisen, Kirsten Kjeldgaard
    Larsen, Finn Ole
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2018, 62 : 61 - 73
  • [33] Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progressionfree survival (PFS) longer than 4 months
    Stein, A.
    Grothey, A.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Humblet, Y.
    Bouche, O.
    Mineur, L.
    Barone, C.
    Adenis, A.
    Tabemero, J.
    Yoshino, T.
    Lenz, H. -J
    Goldberg, R. M.
    Xu, L.
    Wagner, A.
    van Cutsem, E.
    Oncology Research and Treatment, 2015, 38 : 61 - 61
  • [34] Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial
    Knoll, William
    Mallick, Ranjeeta
    Wells, Philip S.
    Carrier, Marc
    BLOOD, 2019, 134
  • [35] Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
    Karasic, Thomas B.
    Brown, Timothy J.
    Schneider, Charles
    Teitelbaum, Ursina R.
    Reiss, Kim A.
    Mitchell, Tara C.
    Massa, Ryan C.
    O'Hara, Mark H.
    DiCicco, Lisa
    Garcia-Marcano, Luis
    Amaravadi, Ravi K.
    O'Dwyer, Peter J.
    ONCOLOGIST, 2022, 27 (09): : 716 - +
  • [36] A Systematic Review and Meta-Analysis of the Efficacy and Safety of Regorafenib in the Treatment of Metastatic Colorectal Cancer
    Liang, Bingjun
    Tang, Ming
    Huang, Chao
    Yang, Yidian
    He, Yue
    Liao, Shengrong
    Shen, Weizeng
    JOURNAL OF GASTROINTESTINAL CANCER, 2025, 56 (01)
  • [37] Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial
    Karthaus, M.
    Schwenke, S.
    Seidel, H.
    Beckmann, G.
    Reischl, J.
    Vonk, R.
    Lenz, H. -J
    Tebernero, J.
    Siena, S.
    Grothey, A.
    van Cutsem, E.
    Jeffers, M.
    Wagner, A.
    Laurent, D.
    Kobina, S.
    Rutstein, M.
    Guinney, J.
    Tejpar, S.
    Oncology Research and Treatment, 2015, 38 : 57 - 58
  • [38] Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
    Taieb, Julien
    Prager, Gerald W.
    Fakih, Marwan
    Ciardello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe Melo
    Wyrwicz, Lucjan S.
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik Paul
    Roby, Lucas
    Barboux, Valentine
    Amellal, Nadia
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 111 - 111
  • [39] Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial
    Teufel, Michael
    Schwenke, Susanne
    Seidel, Henrik
    Beckmann, Georg
    Reischl, Joachim
    Vonk, Richardus
    Lenz, Heinz-Josef
    Tabernero, Josep
    Siena, Salvatore
    Grothey, Axel
    Van Cutsem, Eric
    Jeffers, Michael
    Wilhelm, Scott
    Wagner, Andrea
    Laurent, Dirk
    Kobina, Svetlana
    Rutstein, Mark Daniel
    Wirapati, Pratyaksha
    Guinney, Justin
    Tejpar, Sabine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Time to health status deterioration in regorafenib-treated patients with metastatic colorectal cancer (mCRC): A post-hoc analysis of the phase III CORRECT study
    Chang, J.
    Pawar, V.
    Grothey, A.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Wagner, A.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S546 - S546
12345